Skip to main content

Healthcare is on fire -- is this stock deep value or value trap?

One of the features of this web site is what I refer to as the "super list" where I combine the results of two or more of the screens that the Alert HQ software performs and publish the resulting set of stocks.

Today I'd like to feature a stock that seems to keep popping up on individual screens and was brought to my attention when I checked a few combinations of screens.

This stock is one of the Cash Flow Kings from this past weekend and it's on Tuesday's Trend Leaders list. It's in my recent Q3 Growth Report because it showed gains in both its year-over-year and sequential earnings per share. Finally, it again exceeded it's upper Bollinger Band which earned it a place on Tuesday's Bollinger Band Breakout list.

The name of this stock is Amedisys, Inc and its symbol is AMED.

Normally, I focus on tech stocks but here we have a different animal. Amedisys is a healthcare company. It specializes in home healthcare and hospice services. Here are some snippets from the company's profile on Yahoo Finance: "Its home health services include skilled nursing and home health aide services; physical, occupational, and speech therapy; and medically oriented social work to eligible individuals who require ongoing care... It provides hospice services to patients using an interdisciplinary care team comprising a physician, nurses, home health aides, social workers, therapists, dieticians, volunteers, counselors, chaplains, and bereavement coordinators... As of December 31, 2008, the company owned and operated 480 Medicare-certified home health agencies and 48 Medicare-certified hospice agencies; and managed the operations of 4 Medicare-certified home health and 2 Medicare-certified hospice agencies in 37 states within the United States, the District of Columbia, and Puerto Rico."

Financials --

Amedisys is considered a small-cap; it has a market cap of $1.28 billion. The company seems to be incredibly undervalued. It's trailing PE is 10, it's forward PE is 9, it's PEG is a mere 0.54, price-to-sales is less than 1 and price-to-book is less than 2. The company's Enterprise Value/EBITDA ratio is roughly 6 which is low enough to be approaching the level of "deep value".

As I mentioned above, the company is one of the growth leaders when it comes earnings. Year-over-year EPS growth is 53% though sequential EPS growth slowed down considerably in the latest quarter. Revenue is also growing, up more than 20% year-over-year. So those good EPS numbers are not coming from only cost cutting, there's top line growth going on here. The following chart shows it graphically.

Explore more AMED Data on Wikinvest

Finally, the company is cash flow positive and has no debt.

The technical analysis --

Here we have the chart of daily data for Amedisys.

You can see the stock has surged recently. MACD and Aroon are very bullish. Amedisys has bounced vigorously off its 200-day moving average and moved decisively above the 50-day and 20-day moving averages. The stock seems to be engaging in a textbook upside reversal.

The outlook --

At the time of its last earnings report, Amdedisys reaffirmed its outlook for the year which ends in December. The trailing twelve month EPS is currently $4.53 and the company is projecting that 2009 EPS will be in the range of $4.75 to $4.90. Revenues are also projected to show an increase.

In terms of analyst recommendations, Stifel Nicolaus upgraded the company from Hold to Buy at the end of October.

The fundamentals appear to be terrific but there is considerable controversy surrounding the company. Citron Research has published a highly critical analysis of doings at the company. They point to sudden departures of top executives and note that investigations into Medicare fraud are ramping up and Amedisys has had numerous requests for documents from the government.

To combat this kind of negative analysis, Amedisys engaged Marwood Group Advisory, a healthcare consulting company, to review its "procedures, controls, clinical infrastructure, corporate compliance processes, technology offerings and future strategies." Marwood essentially gave Amedisys a clean bill of health (no pun intended).

Conclusion --

So technically speaking, the stock is showing all kinds of positive behavior. Fundamentally things look pretty good, as well. The issue surrounding Amedisys is whether fraud will upend the company.

On paper this company looks great. For some investors it may take a certain leap of faith to buy into the Amedisys story. Judging by the increase in volume as the stock has surged upward, though, there is a sizable number of other investors who are willing to put aside the negative rumors and just go with the momentum.

Disclosure: no positions


Anonymous said…
Nice analysis. My view is that fraud risk is also mitigated by the large ownership and buy/sell ratio of reputable institutional investors. Rumours have been out there for quite a long time and Goldman, Thornburg and Fidelity chose to substantially increase their position last quarter. Are they ignorant?
Anonymous said…
Dear Author !
Excuse for that I interfere … At me a similar situation. Let's discuss.

Popular posts from this blog

Running TradeRadar on Windows 7 and Windows 8

Development of the original TradeRadar Stock Inspector software was begun back in the days before Windows 7 and Windows 8 were available.

As these newer versions of Windows have become more popular, we have heard from some users that they are having problems installing and running TradeRadar on their newer PCs.

The good news is that TradeRadar will work just fine on Windows 7 and Windows 8. All you have to do is adjust the Windows Compatibility Settings to ensure TradeRadar runs as intended.

It is recommended that you can apply Compatibility Settings when running the initial installation; however, it is also possible to apply Compatibility Settings after the program has been installed.

Prior to installation
After downloading the install program, go to the folder where you have stored the TradeRadarStkInsp_7_Setup.exe or TradeRadarStkInsp_7_PRO_Setup.exe executable. Right-click on the executable file and select Properties. Click the Compatibility tab. Adjust the Compatibility mode to …

Alert HQ has moved!

End of an era!

This site was started way back in 2006/2007 to showcase my blog posts and the Alert HQ buy signals and sell signals. Alert HQ grew to include other kinds of stock alerts including Swing Signals, Trend Busters, Trend Leaders, Cash Flow Kings and more.

In the meantime, I built a sister site, and I started using some of the same Alert HQ content over there. As a result, I am discontinuing the Alert HQ data here at

The good news, however, is that all the Alert HQ signals and stock screens are still completely free. In addition, the pages have been enhanced so that you can hover over a stock symbol and a small chart will pop up so you can get a quick look at the stock's recent price action. If you click on a symbol it will take you to a page with plenty of financial and technical analysis information (still free!) as well as a larger chart that you can play with in terms of adding or deleting indicators, moving averages, etc.

Click …

Durable Goods report for Sept just so-so but Computer segment is on fire

The Durable Goods advanced report for September 2011 was released on Wednesday.

I like to dig into the Durable Goods report because it can be useful for seeing how tech in aggregate is performing and how the sector may perform in the future. I always focus on two particular measures: shipments and new orders. Let's see how it played out last month.

Shipments -- 

I generally give less importance to Shipments since this is a backward looking measure reflecting orders that have been confirmed, manufactured and shipped. It's similar to earnings reports -- it's good to know but the data is in the past and we're more interested in the future. The following chart shows how September shipments looked for the overall tech sector:

Results for the overall tech sector were a bit weak but take a look at the next chart which tracks the Computers and related products segment:

Results here were actually quite good and, to make things even better, the previous month was revised upward.